Text Size:AAA

 VEGFC/VEGF-C/Flt4-L  抗体

All VEGFC Reagents

反应性: Human  
应用 : ELISA  
400 µg 
200 µg 
100 µg 
Add to Cart
    反应性: Human  
    应用 : ELISA  
    50 µg 
    200 µg 
    100 µg 
    Add to Cart

      Browse VEGFC/VEGF-C/Flt4-L Products by

      VEGFC/VEGF-C/Flt4-L 相关研究领域

      VEGFC/VEGF-C/Flt4-L 相关信号通路

      VEGFC/VEGF-C/Flt4-L 相关蛋白、抗体、cDNA基因、ELISA试剂盒

      VEGFC/VEGF-C/Flt4-L 相关蛋白、抗体、cDNA基因、ELISA试剂盒

      Featured Reagent Products

      VEGFC/VEGF-C/Flt4-L 概述&蛋白信息

      VEGFC/VEGF-C/Flt4-L 相关资讯

      VEGFC/VEGF-C/Flt4-L 研究背景

      亚单位结构: Homodimer; non-covalent and antiparallel. {ECO:0000269|PubMed:20145116}.
      亚细胞定位: Secreted.
      组织特异性: Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.
      翻译后修饰: Undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGF-C first form an antiparallel homodimer linked by disulfide bonds. Before secretion, a cleavage occurs between Arg-227 and Ser-228 producing a heterotetramer. The next extracellular step of the processing removes the N-terminal propeptide. Finally the mature VEGF-C is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.
      相关疾病 : DISEASE: Lymphedema, hereditary, 1D (LMPH1D) [MIM:615907]: A chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment. {ECO:0000269|PubMed:23410910, ECO:0000269|PubMed:24744435}. Note=The disease is caused by mutations affecting the gene represented in this entry.
      相似的序列: Belongs to the PDGF/VEGF growth factor family. {ECO:0000305}.
      General information above from UniProt

      Vascular endothelial growth factor C (VEGF-C) is a member of the VEGF family. Upon biosynthesis, VEGF-C protein is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF-C protein is a dimeric glycoprotein, as a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. VEGF-C may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis. VEGF-C protein is over-expressed in various human cancers including breast cancer and prostate cancer. VEGF-C/VEGFR-3 axis, through different signaling pathways, plays a critical role in cancer progression by regulating different cellular functions, such as invasion, proliferation, and resistance to chemotherapy. Thus, targeting the VEGF-C/VEGFR-3 axis may be therapeutically significant for certain types of tumors.

      VEGFC/VEGF-C/Flt4-L 别称

      VEGFC/VEGF-C/Flt4-L 相关文献

    • Joukov V, et al. (1997) Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol. 173(2): 211-5.
    • Su JL, et al. (2007) The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer. 96(4): 541-5.
    • Anisimov A, et al. (2009) Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 104(11): 1302-12.
    • 请注意:所有产品都是“仅用于科研,而不能用于诊断或治疗用途”